Clincosm LogoSign in Get a demo

tislelizumab

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

Tislelizumab Combined With Chemotherapy in First-line Treatment

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023

Tislelizumab, Bevacizumab, Oxaliplatin Trial in Beijing (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Recruiting
  • Tislelizumab
  • +7 more
  • Beijing, China
    Lin Yang
Jul 21, 2023

Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +5 more
  • TACE
  • Tislelizumab, Lenvatinib
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • +3 more
  • (no location specified)
Apr 23, 2023

Tislelizumab, Lenvatinib, TACE Trial in Nanning (Tislelizumab and Lenvatinib)

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Tislelizumab and Lenvatinib
  • Nanning, Guangxi, China
    The Affiliated Cancer Hospital of Guangxi Medical University
Jan 25, 2023

Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Institute & Hospital
May 24, 2022

Pulmonary Pleomorphic Carcinoma, Immunotherapy, Tislelizumab Trial in Nanchang (Tislelizumab in combination with anlotinib)

Recruiting
  • Pulmonary Pleomorphic Carcinoma
  • +2 more
  • Tislelizumab in combination with anlotinib
  • Nanchang, Jiangxi, China
    The Second Afiliated Hospital of Nanchang University
May 10, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Tislelizumab, Safety, Biomarker Trial in Guangzhou, Jiangmen (Tislelizumab 200 mg, Carboplatin AUC 5, pemetrexed 500mg/m2)

Recruiting
  • Tislelizumab
  • +3 more
  • Tislelizumab 200 mg
  • +4 more
  • Guangzhou, Guangdong, China
  • +3 more
Feb 8, 2022

Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab Trial in Shanghai (Tislelizumab plus chemo)

Recruiting
  • Cancer of Unknown Primary
  • +5 more
  • Tislelizumab plus chemotherapy
  • Shanghai, Shanghai, China
    ChangZheng Hospital
Feb 6, 2022

Tislelizumab, Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment Trial in Changchun (Tilelimumab)

Not yet recruiting
  • Tislelizumab
  • +3 more
  • Changchun, Jilin, China
    First Hospital of Jilin University
May 26, 2021